Skip to main content
SpringerLink
Log in

Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Activation of CB1 cannabinoid receptors by exogenous agonists causes presynaptic inhibition of neurotransmitter release from axon terminals. In the central nervous system, presynaptic CB1 receptors can also be activated by endogenous cannabinoids (endocannabinoids) released from postsynaptic neurons. Except in the vas deferens, there is no indication of endocannabinoid-mediated presynaptic inhibition in the sympathetic nervous system. The aim of the present study was to search for such inhibition in pithed rats. Artificial sympathetic tone was established by continuous electrical stimulation of preganglionic sympathetic axons. The CB1 cannabinoid receptor antagonist rimonabant (0.5 and 2 mg kg−1 i.v.) did not change blood pressure, heart rate or plasma noradrenaline concentration. Since activation of Gαq/11 protein-coupled receptors enhances endocannabinoid synthesis in the central nervous system, we attempted to stimulate endocannabinoid production by infusion of arginine vasopressin and phenylephrine (both activate Gαq/11 protein-coupled receptors). Rimonabant (2 mg kg−1 i.v.) did not change blood pressure, heart rate or plasma noradrenaline concentration during infusion of phenylephrine or vasopressin. In the final series of experiments we verified that an exogenous cannabinoid agonist produces sympathoinhibition. The synthetic CB1/CB2 receptor agonist WIN55212-2 (0.1 and 1 mg kg−1 i.v.) markedly lowered blood pressure and plasma noradrenaline concentration in pithed rats with electrically stimulated sympathetic outflow. In contrast, in pithed rats with a pressor infusion of noradrenaline, WIN55212-2 did not change blood pressure or heart rate. The results verify that activation of peripheral presynaptic CB1 receptors inhibits noradrenaline release from sympathetic nerve terminals. The lack of effect of the CB1 receptor antagonist rimonabant indicates that, even under conditions favouring endocannabinoid synthesis, endocannabinoid-mediated presynaptic inhibition is not operating in the sympathetic nervous system of the pithed rat.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a–c
Fig. 2a–c
Fig. 3
Fig. 4a–c
Fig. 5a–c
Fig. 6a–c

Similar content being viewed by others

References

  • Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek R, Garcia N Jr, Sanyal AJ, Kunos G (2001) Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7:827–832

    Article  Google Scholar 

  • Brown SP, Brenowitz SD, Regehr WG (2003) Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nat Neurosci 6:1048–1057

    Article  Google Scholar 

  • Christopoulos A, Coles P, Lay L, Lew MJ, Angus JA (2001) Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Br J Pharmacol 132:1281–1291

    Google Scholar 

  • Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21:521–528

    Article  PubMed  Google Scholar 

  • Fernandez JR, Allison DB (2004) Rimonabant Sanofi-Synthelabo. Curr Opin Invest Drugs 5:430–435

    Google Scholar 

  • Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017–1066

    CAS  PubMed  Google Scholar 

  • Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR (1999) Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit l-type Ca2+ channel current. Am J Physiol 276:H2085–H2093

    Google Scholar 

  • Godlewski G, Malinowska B, Schlicker E (2004) Presynaptic cannabinoid CB1 receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. Br J Pharmacol 142:701–708

    Google Scholar 

  • Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) Classification of cannabinoid receptors. International Union of Pharmacology XXVII. Pharmacol Rev 54:161–202

    Article  Google Scholar 

  • Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G (1996) Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023–2028

    Google Scholar 

  • Izzo AA, Mascolo N, Borrelli F, Capasso F (1998) Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br J Pharmacol 124:1363–1368

    Google Scholar 

  • Kathmann M, Schultheiss T, Flau K, Redmer A, Reggio PH, Seltzman HH, Schlicker E (2004) SR141716 increases but VCHSR does not affect transmitter release in guinea-pig hippocampus. 2004 Symposium on the Cannabinoids, International Cannabinoid Research Society, Burlington, Vermont, p 156

    Google Scholar 

  • Kim J, Isokawa M, Ledent C, Alger BE (2002) Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci 22:10182–10191

    Google Scholar 

  • Le Fur G (2004) Pharmacology of cannabinoid receptor antagonists—possible therapeutic applications. Fundam Clin Pharmacol 18 (suppl 1):9

    Google Scholar 

  • Levenes C, Daniel H, Soubrie P, Crepel F (1998) Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol (Lond) 510:867–879

    Article  Google Scholar 

  • Li J, Kaminski NE, Wang DH (2003) Anandamide-induced depressor effect in spontaneously hypertensive rats. Hypertension 41:757–762

    Article  Google Scholar 

  • MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW (1998) Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 124:619–622

    Google Scholar 

  • Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M (2001) Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31:463–475

    Article  CAS  PubMed  Google Scholar 

  • Malinowska B, Godlewski G, Bucher B, Schlicker E (1997) Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn-Schmiedebergs Arch Pharmacol 356:197–202

    Google Scholar 

  • Malinowska B, Kwolek G, Göthert M (2001a) Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn-Schmiedebergs Arch Pharmacol 364:562–569

    Article  Google Scholar 

  • Malinowska B, Piszcz J, Koneczny B, Hryniewicz A, Schlicker E (2001b) Modulation of the cardiac autonomic transmission of pithed rats by presynaptic opioid OP4 and cannabinoid CB1 receptors. Naunyn-Schmiedebergs Arch Pharmacol 364:233–241

    Article  Google Scholar 

  • Mechoulam R, Fride E, Ben-Shabat S, Meiri U, Horowitz M (1998) Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol 362:R1–R3

    Article  Google Scholar 

  • Niederhoffer N, Szabo B (1999) Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 126:457–466

    Google Scholar 

  • Niederhoffer N, Schmid K, Szabo B (2003) The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn-Schmiedebergs Arch Pharmacol 367:434–443

    Google Scholar 

  • Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635–664

    CAS  PubMed  Google Scholar 

  • Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD (1992) Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol 105:980–984

    Google Scholar 

  • Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca F (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21:218–224

    Google Scholar 

  • Ralevic V, Kendall DA (2002) Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. Eur J Pharmacol 444:171–181

    Article  Google Scholar 

  • Schlicker E, Kathmann M (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565–572

    Google Scholar 

  • Schlicker E, Redmer A, Werner A, Kathmann M (2003) Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release. Br J Pharmacol 140:323–328

    Google Scholar 

  • Schmid K, Niederhoffer N, Szabo B (2003) Analysis of the respiratory effects of cannabinoids in rats. Naunyn-Schmiedebergs Arch Pharmacol 368:301–308

    Article  Google Scholar 

  • Szabo B, Fritz, T, Wedzony K (2001a) Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex. Br J Pharmacol 134:295–304

    Google Scholar 

  • Szabo B, Nordheim U, Niederhoffer N (2001b) Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 297:819–826

    Google Scholar 

  • Szallasi A, Di Marzo V (2000) New perspectives on enigmatic vanilloid receptors. Trends Neurosci 23:491–497

    Article  Google Scholar 

  • Trendelenburg AU, Cox SL, Schelb V, Klebroff W, Khairallah L, Starke K (2000) Modulation of 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and beta-adrenoceptors in mouse tissues. Br J Pharmacol 130:321–330

    CAS  PubMed  Google Scholar 

  • Varga K, Wagner JA, Bridgen DT, Kunos G (1998) Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12:1035–1044

    Google Scholar 

  • Vizi ES, Katona I, Freund TF (2001) Evidence for presynaptic cannabinoid CB(1) receptor-mediated inhibition of noradrenaline release in the guinea pig lung. Eur J Pharmacol 431:237–244

    Article  Google Scholar 

  • Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390:518–521

    Article  Google Scholar 

  • Wagner JA, Varga K, Kunos G (1998) Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 76:824–836

    Article  Google Scholar 

  • Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, Goparaju SK, Kunos G, Ertl G (2001a) Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 38:2048–2054

    Article  Google Scholar 

  • Wagner JA, Jarai Z, Batkai S, Kunos G (2001b) Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur J Pharmacol 423:203–210

    Article  Google Scholar 

  • Wallmichrath I, Szabo B (2002) Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 113:671–682

    Article  Google Scholar 

  • Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588–592

    Article  Google Scholar 

  • Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296:678–682

    Article  CAS  PubMed  Google Scholar 

  • Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452–457

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study was supported by the Deutsche Forschungsgemeinschaft (Ni 644/1-1; Sz 72/5-1). We thank Claudia Schurr for the catecholamine analysis and Klaus Starke for the support and advice. The supply of rimonabant by Sanofi-Synthélabo (Montpellier, France) is gratefully acknowledged.

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Albert-Ludwigs-Universität, Albertstrasse 25, 79104, Freiburg i. Br., Germany

    Torsten Pfitzer, Nathalie Niederhoffer & Bela Szabo

Authors
  1. Torsten Pfitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathalie Niederhoffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bela Szabo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bela Szabo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pfitzer, T., Niederhoffer, N. & Szabo, B. Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system. Naunyn-Schmiedeberg's Arch Pharmacol 371, 9–17 (2005). https://doi.org/10.1007/s00210-004-1003-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-004-1003-9

Keywords

Search

Navigation